U.K. study shows Victoza reduces HbA1c better than Byetta, DPP-4s
14:34 EDT 11 Jun 2012 | BioCentury
Researchers at Llandough Hospital reported data compiled from U.K. primary care practices showing that subcutaneous Victoza liraglutide produced significantly greater mean reductions in HbA1c compared to both subcutaneous Byetta exenatide and treatme..
Original Article: U.K. study shows Victoza reduces HbA1c better than Byetta, DPP-4s
More From BioPortfolio on "U.K. study shows Victoza reduces HbA1c better than Byetta, DPP-4s"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
